Latest News
View More
The big interview: Cisco UK and Ireland CEO David Meads
Foreseeing a global pandemic is not in any business leader’s job description. But perhaps the most vital skill for today’s…
Latest News
View More
AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD). The…
Israel to initiate human trials of potential Covid-19 vaccine
The Israel Institute for Biological Research (IIBR) has obtained regulatory approval to initiate human clinical trials for its Covid-19 vaccine candidate on 1 November. The…
Lilly and Boehringer report positive outcomes in heart failure trial
Eli Lilly and Boehringer Ingelheim have reported that new exploratory sub-analysis data from the EMPEROR-Reduced Phase III trial showed Jardiance…
Dicerna’s nedosiran achieves urinary oxalate normalisation in PH trial
Dicerna Pharmaceuticals has reported positive interim data from its ongoing PHYOX3 trial of investigational drug candidate, nedosiran, for the treatment of…
Goldfinch Bio reports positive data from GFB-887 trial
Goldfinch Bio has reported positive results from its Phase I clinical trial of GFB-887, a highly potent and selective inhibitor…
Moderna completes enrolment for mRNA-1273 trial against Covid-19
Moderna has completed the enrolment of participants for the Phase III COVE study of its vaccine candidate, mRNA-1273, against Covid-19.…
Expert Commentary & Analysis
View MorePositive data for Amylyx’s AMX0035 strengthen its position to enter ALS market
On October 16, Amylyx announced that AMX0035, its amyotrophic lateral sclerosis (ALS) pipeline drug, showed potential to prolong patient survival and slow rapid disease progression in ALS patients. The results…
Trials disrupted due to Covid-19 continue to resume
Since early March, more than 500 companies have publicly announced clinical trial disruptions, both planned and ongoing, due to the Covid-19 pandemic. Many companies have delayed the initiation of planned…
Positive vote from FDA’s Advisory Committee for Alkermes’ ALKS-3831 strengthens its potential position in the Schizophrenia market
On the 9th of October, Alkermes announced positive voting from the joint meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee…
Interim results of the SOLIDARITY trial failed to show efficacy of repurposed drugs in mortality of hospitalized Covid-19 patients
The World Health Organization’s Phase II/III SOLIDARITY trial for COVID-19 is currently the world’s largest randomized clinical trial for the treatment of COVID-19, with 11,266 patients enrolled from 405 hospitals…